Sensei Biotherapeutics, Inc. (NASDAQ:SNSE – Get Free Report)’s share price fell 1.3% during mid-day trading on Wednesday . The company traded as low as $0.44 and last traded at $0.46. 37,044 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 114,842 shares. The stock had previously closed at $0.47.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a “buy” rating and set a $4.00 price objective on shares of Sensei Biotherapeutics in a report on Wednesday, August 7th.
Check Out Our Latest Stock Analysis on Sensei Biotherapeutics
Sensei Biotherapeutics Stock Performance
Sensei Biotherapeutics (NASDAQ:SNSE – Get Free Report) last issued its earnings results on Tuesday, August 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.01. Research analysts predict that Sensei Biotherapeutics, Inc. will post -1.11 earnings per share for the current fiscal year.
About Sensei Biotherapeutics
Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.
Featured Articles
- Five stocks we like better than Sensei Biotherapeutics
- What is a Secondary Public Offering? What Investors Need to Know
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- Short Selling: How to Short a Stock
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.